1. The A to I editing landscape in melanoma and its relation to clinical outcome
- Author
-
Amweg, Austeja, Tusup, Marina, Cheng, Phil, Picardi, Ernesto, Dummer, Reinhard, Levesque, Mitchell P, French, Lars E, Guenova, Emmanuella, Läuchli, Severin, Kündig, Thomas, Mellett, Mark, Pascolo, Steve, University of Zurich, and Mellett, Mark
- Subjects
Proto-Oncogene Proteins B-raf ,Ubiquitin-Protein Ligases ,RNA-Binding Proteins ,10177 Dermatology Clinic ,610 Medicine & health ,Cell Biology ,1307 Cell Biology ,Cell Line, Tumor ,Mutation ,1312 Molecular Biology ,Humans ,RNA Editing ,Melanoma ,Molecular Biology - Abstract
RNA editing refers to non-transient RNA modifications that occur after transcription and prior to translation by the ribosomes. RNA editing is more widespread in cancer cells than in non-transformed cells and is associated with tumorigenesis of various cancer tissues. However, RNA editing can also generate neo-antigens that expose tumour cells to host immunosurveillance. Global RNA editing in melanoma and its relevance to clinical outcome currently remain poorly characterized. The present study compared RNA editing as well as gene expression in tumour cell lines from melanoma patients of short or long metastasis-free survival, patients relapsing or not after immuno- and targeted therapy and tumours harbouring
- Published
- 2022